Royal Bank of Canada’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-13,465
| Closed | -$61K | – | 7114 |
|
|
2025
Q3 | $61K | Buy |
13,465
+10,696
| +386% | +$31.5K | ﹤0.01% | 5734 |
|
|
2025
Q2 | $6K | Buy |
2,769
+216
| +8% | +$604 | ﹤0.01% | 6590 |
|
|
2025
Q1 | $11K | Sell |
2,553
-1,003
| -28% | -$4.52K | ﹤0.01% | 6114 |
|
|
2024
Q4 | $16K | Buy |
3,556
+1,410
| +66% | +$9.49K | ﹤0.01% | 6185 |
|
|
2024
Q3 | $15K | Sell |
2,146
-88
| -4% | -$639 | ﹤0.01% | 6191 |
|
|
2024
Q2 | $15K | Buy |
2,234
+2,223
| +20,209% | +$20.7K | ﹤0.01% | 6172 |
|
|
2024
Q1 | $0 | Buy |
11
+5
| +83% | +$76 | ﹤0.01% | 6950 |
|
|
2023
Q4 | $0 | Buy |
6
+2
| +50% | +$18 | ﹤0.01% | 7056 |
|
|
2023
Q3 | $0 | Sell |
4
-236
| -98% | -$4.24K | ﹤0.01% | 7027 |
|
|
2023
Q2 | $4K | Buy |
240
+69
| +40% | +$726 | ﹤0.01% | 6713 |
|
|
2023
Q1 | $1K | Buy |
171
+30
| +21% | +$212 | ﹤0.01% | 6855 |
|
|
2022
Q4 | $1K | Sell |
141
-110
| -44% | -$834 | ﹤0.01% | 6992 |
|
|
2022
Q3 | $2K | Buy |
251
+222
| +766% | +$2.92K | ﹤0.01% | 6976 |
|
|
2022
Q2 | $0 | Sell |
29
-505
| -95% | -$5.29K | ﹤0.01% | 7320 |
|
|
2022
Q1 | $7K | Sell |
534
-1,027
| -66% | -$15K | ﹤0.01% | 7098 |
|
|
2021
Q4 | $27K | Buy |
1,561
+733
| +89% | +$14.7K | ﹤0.01% | 6654 |
|
|
2021
Q3 | $18K | Buy |
828
+108
| +15% | +$2.76K | ﹤0.01% | 6738 |
|
|
2021
Q2 | $25K | Sell |
720
-296
| -29% | -$15.9K | ﹤0.01% | 6438 |
|
|
2021
Q1 | $100K | Buy |
1,016
+790
| +350% | +$94.9K | ﹤0.01% | 5462 |
|
|
2020
Q4 | $25K | Buy |
226
+126
| +126% | +$15.6K | ﹤0.01% | 5950 |
|
|
2020
Q3 | $10K | Sell |
100
-421
| -81% | -$63K | ﹤0.01% | 5918 |
|
|
2020
Q2 | $109K | Buy |
521
+390
| +298% | +$69.1K | ﹤0.01% | 4799 |
|
|
2020
Q1 | $13K | Sell |
131
-102
| -44% | -$11.9K | ﹤0.01% | 5717 |
|
|
2019
Q4 | $27K | Buy |
+233
| New | +$20.5K | ﹤0.01% | 5724 |
|
|
2018
Q4 | – | Sell |
-94
| Closed | -$6K | – | 6692 |
|
|
2018
Q3 | $6K | Buy |
+94
| New | +$5.28K | ﹤0.01% | 6163 |
|
|
2018
Q1 | – | Sell |
-565
| Closed | -$20K | – | 6292 |
|
|
2017
Q4 | $20K | Sell |
565
-2
| -0.4% | -$66 | ﹤0.01% | 5595 |
|
|
2017
Q3 | $21K | Buy |
567
+2
| +0.4% | +$56 | ﹤0.01% | 5913 |
|
|
2017
Q2 | $14K | Sell |
565
-87
| -13% | -$2.38K | ﹤0.01% | 5674 |
|
|
2017
Q1 | $17K | Buy |
652
+23
| +4% | +$654 | ﹤0.01% | 5703 |
|
|
2016
Q4 | $18K | Buy |
629
+64
| +11% | +$2.09K | ﹤0.01% | 5823 |
|
|
2016
Q3 | $23K | Hold |
565
| – | – | ﹤0.01% | 5494 |
|
|
2016
Q2 | $18K | Hold |
565
| – | – | ﹤0.01% | 5543 |
|
|
2016
Q1 | $29K | Sell |
565
-506
| -47% | -$28.3K | ﹤0.01% | 5352 |
|
|
2015
Q4 | $101K | Buy |
1,071
+974
| +1,004% | +$85.6K | ﹤0.01% | 4924 |
|
|
2015
Q3 | $8K | Sell |
97
-25
| -20% | -$3.19K | ﹤0.01% | 5974 |
|
|
2015
Q2 | $20K | Buy |
+122
| New | +$41.2K | ﹤0.01% | 5697 |
|
Royal Bank of Canada's ADVM Position: Q4 2025 in Review
Royal Bank of Canada sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 13,465 shares — an estimated $61K sold.
Royal Bank of Canada first reported a position in ADVM in Q2 2015 and held it in 36 quarters. The position peaked at $109K in Q2 2020. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- Royal Bank of Canada reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- Royal Bank of Canada sold 13,465 Adverum Biotechnologies shares in Q4 2025, an estimated $61K.
- Royal Bank of Canada first reported a position in Adverum Biotechnologies in Q2 2015 and held it in 36 quarters.
- Royal Bank of Canada's Adverum Biotechnologies position peaked at $109K in Q2 2020.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on Royal Bank of Canada's 13F filing for Q4 2025, filed 17 Feb 2026.